The FDA has cleared IB-Stim as the first treatment specifically indicated for pediatric functional dyspepsia and related nausea, providing a noninvasive neuromodulation option for abdominal pain in patients aged 8 to 21 years.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.
FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.
Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.